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The role of reactive oxygen species (ROS) in hypercholes-terolemia-induced atherosclerosis has been previously 
reported (1,2). Hypercholesterolemia stimulates polymorpho-
nuclear leukocytes and activates vascular endothelial cells, 
which results in excess ROS release (3,4). In addition, hyper-
cholesterolemia increases platelet-activating factor concentra-
tions, which in turn increases interleukin (IL)-1b and tumour 
necrosis factor-alpha (TNF-a) synthesis and release (5). IL-1b, 
IL-8 and IL-6, TNF-a and interferon-gamma are known to 
activate granulocytes that generate ROS (6). TNF-a also indu-
ces NADPH-oxidase enzyme to liberate ROS in the vascular 
endothelial cells (7).
Thymoquinone (TQ) (2-isopropyl-5-methyl-1,4-benzo-
quinone) is the bioactive constituent of the volatile oil of 
Nigella sativa seeds (8). The oil and seed constituents, in par-
ticular TQ, have shown potential medicinal properties in trad-
itional medicine. N sativa seeds have long been used in folk 
medicine for a wide range of illnesses including bronchial 
asthma, headache, dysentery, infections, obesity, back pain, 
hypertension and gastrointestinal problems (9). TQ has anti-
oxidant and anti-inflammatory activities (10), as well as lipid- 
lowering effects (11). 
Because of these pharmacological properties, it is hypoth-
esized that TQ may attenuate hypercholesterolemia and the 
development of hypercholesterolemic atherosclerosis. The 
main objectives of the present study were to investigate 
whether TQ attenuates the development of atherosclerosis, 
whether this effect is associated with reduction in serum lipids and 
oxidative stress, and whether the effects are dose-dependent. 
Methods
drugs
TQ (Sigma-Aldrich, USA) was dissolved in pure corn oil 
(Sigma-Aldrich, USA) to give a concentration of 75 mg/mL. 
Animals and experimental design
Twenty-four female New Zealand white rabbits, weighing 
1.8 kg to 2 kg and aged six to eight weeks, were assigned to four 
groups. After one week of adaptation, the rabbits were fed a 
regular diet (group I), a high-cholesterol diet alone (group II), or 
a high-cholesterol diet plus TQ 10 mg/kg/day or 20 mg/kg/day 
(groups III and IV) for eight weeks. The diet was prepared by 
Purina (USA) and did not contain any antioxidants. TQ was 
given through nasogastric tubes. Water was given ad libitum. 
The rabbits were housed in individual cages at room temper-
ature (22°C to 24°C) and a relative humidity of 40% to 60% 
under a 12 h light/12 h dark cycle. The experimental protocols 
were approved by the Ethics Committee of the University of 
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Thymoquinone (TQ), derived from Nigella sativa seed, is an antioxidant. 
The present study investigated whether TQ attenuates the development of 
atherosclerosis, and/or reduces the serum lipid levels and oxidative stress in 
rabbits. New Zealand white female rabbits were assigned to four groups of 
six animals each: group I, control; group II, 1% cholesterol diet; group 
III, 1% cholesterol plus TQ (10 mg/kg/day; through a nasogastric tube) 
diet; and group IV, 1% cholesterol plus TQ (20 mg/kg/day; through a 
nasogastric tube) diet. Blood samples were collected at baseline and 
after four and eight weeks on the experimental diets for measurement 
of serum lipids, total cholesterol (TC), triglycerides (TG), low-den-
sity lipoprotein cholesterol (LDL-C), high-density lipoprotein cho-
lesterol (HDL-C), TC/HDL-C ratio and oxidative stress biomarkers 
(malondialdehyde [MDA] and protein carbonyls). At the end of the 
eight weeks, the aorta was removed for the assessment of atheroscle-
rotic changes, MDA and protein carbonyls. Group II animals devel-
oped atherosclerosis (45%±11% of the intimal surface of aorta was 
covered with atherosclerotic plaques), which was associated with an 
increase in the serum TC, TG, LDL-C, HDL-C, TC/HDL-C, MDA 
and protein carbonyls. In group III, TQ decreased serum TC, LDL-C, 
MDA and protein carbonyls by 26%, 29%, 85% and 62%, respectively, 
and aortic MDA by 73%, which was associated with a 40% reduction 
of the development of aortic atherosclerosis. The higher dose of TQ in 
group IV had effects similar to the lower dose (group III), except that 
this dose further decreased serum TG. It is concluded that TQ attenu-
ates hypercholesterolemic atherosclerosis and this effect is associated 
with a decrease in serum lipids and oxidative stress.
Key Words: Atherosclerosis; Hypercholesterolemia; Reactive oxygen spe-
cies; Thymoquinone
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Saskatchewan, Saskatoon, Saskatchewan, and the animal care 
was according to the approved standards for Laboratory Animal 
Care. Following 18 h of fasting, blood samples (from the ear 
marginal vein) were collected before (zero week), and after 
four and eight weeks on the respective diets for measurement of 
total cholesterol (TC), triglycerides (TG), low-density lipopro-
tein cholesterol (LDL-C), high-density lipoprotein cholesterol 
(HDL-C), TC/HDL-C and serum malondialdehyde (MDA). 
Serum protein carbonyls was measured only at week 8. At the 
end of the study (eight weeks), rabbits were anesthetized with 
Euthanyl (sodium pentobarbital; Bimeda-MTC Animal Health 
Inc, Canada) (50 mg/kg intravenously) in the marginal ear 
vein. Aortas were removed for the assessment of atheroscler-
otic changes, and measurement of aortic MDA and protein 
carbonyls. 
serum lipids
TC, TG and HDL-C were measured on an automated Synchron 
LX20 Clinical System Analyzer (Beckman Coulter Inc, USA). 
LDL-C was calculated. Risk ratio was estimated using the quo-
tient TC/HDL-C.
Preparation of the aortic tissue for measurement of MdA 
and protein carbonyls
The aortic rings were excised at the roots of the aortic arches 
and kept in 10% buffered formalin for histological examina-
tion. Aortas between the origin and bifurcation to the iliac 
arteries were removed, cleansed of gross adventitial tissue and 
cut longitudinally into two halves. One half was used for assess-
ment of atherosclerotic changes, and the other half was kept on 
ice for preparation of the supernatants, by a previously 
described method (12), for measurement of the aortic tissue 
MDA and protein carbonyls. 
serum and aortic MdA (thiobarbituric acid-reactive 
substances)
MDA levels in the aortic tissue supernatant and serum were 
measured as thiobarbituric acid-reactive substances by a previ-
ously described method (12,13). Thiobarbituric acid-reactive 
substances were extracted in a mixture of butanol and pyridine 
(15:1) that was separated by centrifugation. The fluorescence 
intensity of the butanol-pyridine solution was measured at 
553 nm with excitation at 513 nm. The MDA content of the 
tissue was expressed as nmol/mg proteins and that of serum as 
nmol/mL.
serum and aortic protein carbonyls 
The protein carbonyl levels in the aortic tissue supernatant and 
serum were measured using a Cayman Chemical Carbonyl 
Protein Assay Kit (Cayman Chemical Company, USA). The 
absorbance was measured at wavelengths between 360 nm and 
386 nm using an ELx 808TM Absorbance Microplate Reader 
(BioTek Instruments Inc, USA). The protein carbonyl content 
of the tissue was expressed as nmol/mg proteins and that of 
serum as nmol/mL.
tissue protein measurement
Protein content was determined using a Modified Lowry Protein 
Assay Kit (Pierce Biotechnology, USA). The absorbance was 
measured at a wavelength of 750 nm using an ELx 808TM 
Absorbance Microplate Reader.
Assessment of atherosclerotic changes in the aorta
Assessment of atherosclerotic changes in the aorta was per-
formed by using Herxheimer’s solution containing Sudan IV 
for lipid staining, as described previously (3,14). Photographs 
of the stained intimal surface of the aorta were taken with a 
digital camera. The total and atherosclerotic areas of the 
intimal surface of the aorta were measured using Scion Image 
for Windows (Scion Corporation, USA) image analysis soft-
ware. The extent of atherosclerosis was expressed as a percent-
age of total intimal surface area.
histological examination
The aortic ring specimens were crosswise and embedded in 
paraffin. Paraffin sections of 4 µm thickness were cut and 
stained with hematoxylin and eosin (H&E) and examined by 
light microscopy. A Sigma-Aldrich Accustain Elastic Stain Kit 
(Sigma-Aldrich Canada Ltd) was used to visualize elastic lam-
inae and examine the changes in the elastic fibres by light 
microscopy.
Quantification and histological assessment of atherosclerotic 
lesions in aortic rings
Sections stained with H&E were used to compare the total 
cross-sectional intimal and medial areas and the intima/media 
thickness (I/M) ratio between the groups. Using Scion Image 
for Windows image analysis software, the total cross-sectional 
intimal area was measured between the endothelial cell mono-
layer and the internal elastic lamina (IEL), and the total cross-
sectional medial area was measured between the external 
elastic lamina and the IEL. The intimal and medial surface 
areas, as well as the I/M ratio, were taken as measures of the 
severity of atherosclerosis (15).
statistical analysis
Results were expressed as mean ± SD. Repeated-measures 
ANOVA was used for statistical analysis.  A value of P<0.05 
was considered to be significant.
Results
Body weight
Sequential changes of the body weight of the rabbits in the four 
groups at zero, four and eight weeks were documented in kilo-
grams. Compared with baseline measurements, there was a 
significant increase in the body weight in all groups at eight 
weeks. At zero, four and eight weeks, the mean weights in 
group I were 1.74±015 kg, 2.45±0.08 kg and 2.92±0.12 kg, 
respectively. In group II, the weights were 1.8±0.07 kg, 
2.5±0.13 kg and 2.95±0.09 kg, respectively, and in group III, 
the respective weights were 1.78±0.09 kg, 2.56±0.14 kg and 
2.94±0.22 kg. In group IV, the weights were 1.75±0.1 kg, 
2.45±0.22 kg and 2.93±0.20 kg, respectively. No significant 
differences in weights were observed among the groups through-
out the study period.
serum lipids
The baseline levels of serum TC in groups I, II, III and IV were 
1.38±0.2 mmol/L, 1.26±0.3 mmol/L, 1.5±0.7 mmol/L and 
1.5±0.3 mmol/L, respectively. The baseline levels were not 
significantly different among the groups. The sequential chan-
ges in serum TC in the four groups are shown in Figure 1. 
Serum levels of TC remained unchanged in group I with 
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respect to zero time. Serum levels of TC were elevated in 
groups II, III and IV compared with their basal levels and these 
levels were higher compared with those in group I at weeks 4 
and 8. The levels at week 8 were not different from those at 
week 4 in all groups, and these levels were lower in groups III 
and IV compared with group II.  
The baseline levels of serum TG in groups I, II, III and IV 
were 0.79±0.2 mmol/L, 1.02±0.3 mmol/L, 0.62±0.1 mmol/L 
and 0.45±0.1 mmol/L, respectively. The baseline levels were 
not significantly different among the groups. The sequential 
changes in serum TG in the four groups are shown in Figure 1. 
Serum levels of TG remained unchanged in group I with respect 
to zero time. Serum levels of TG increased in groups II, III and 
IV compared with the initial levels and these levels were higher 
compared with those in group I at weeks 4 and 8. The levels at 
week 8 were not different from those at week 4 in all groups and 
these levels were lower in group IV compared with group III.  
The baseline levels of serum LDL-C in groups I, II, III and IV 
were 0.4±0.2 mmol/L, 0.35±0.2 mmol/L, 0.72±0.7 mmol/L and 
0.59±0.3 mmol/L, respectively, and were not significantly differ-
ent from each other. The sequential changes in LDL-C in the 
four groups are shown in Figure 2. Serum levels of LDL-C 
remained unchanged in group I with respect to zero time. Serum 
LDL-C levels increased in groups II, III and IV compared with 
the baseline levels and these levels were higher compared with 
those in group I at weeks 4 and 8. LDL-C levels at week 8 were 
not different from those at week 4 in all groups and these levels 
were lower in groups III and IV compared with group II.  
Figure 1) Sequential changes in serum total cholesterol (TC) and triglycerides (TG) in the four groups. Results are expressed as mean ± SD. 
Group I: normal diet; group II: 1% cholesterol diet; group III: 1% cholesterol diet plus thymoquinone 10 mg/kg/day; group IV: 1% cholesterol 
diet plus thymoquinone 20 mg/kg/day. aP<0.05, zero time versus four and eight weeks in the respective groups; bP<0.05, group I versus other 
groups; cP<0.05, group II versus groups III or IV; dP<0.05, group III versus group IV
Figure 2) Sequential changes in serum low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) in the 
four experimental groups. Results are expressed as mean ± SD. Group I: normal diet; group II: 1% cholesterol diet; group III: 1% cholesterol 
diet plus thymoquinone 10 mg/kg/day; group IV: 1% cholesterol diet plus thymoquinone 20 mg/kg/day. aP<0.05, zero time versus four and 
eight weeks in the respective groups; bP<0.05, group I versus other groups; cP<0.05, group II versus groups III or IV
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The initial levels of serum HDL-C in groups I, II, III and IV 
were 0.62±0.2 mmol/L, 0.44±0.2 mmol/L, 0.49±0.2 mmol/L 
and 0.7±0.1 mmol/L, respectively, and were not significantly 
different among the groups. The sequential changes in HDL-C 
in the four groups are shown in Figure 2. Serum levels of 
HDL-C remained unchanged in group I with respect to zero 
time. Serum HDL-C levels increased in groups II, III and IV 
compared with their initial levels and these levels were higher 
compared with those in group I at weeks 4 and 8. HDL-C levels 
at week 8 were not different from those at week 4 in all groups 
and these levels were lower in groups III and IV compared with 
group II at weeks 4 and 8.  
The baseline values of the risk ratio TC/HDL-C in groups I, 
II, III and IV were 2.31±0.4, 3.04±1, 3.03±1 and 2.15±0.3, 
respectively. The basal values were not significantly different 
among the groups. The sequential changes in the risk ratio in 
the four groups are shown in Figure 3. The risk ratio remained 
unchanged in group I and increased in groups II, III and IV 
with respect to zero time. The risk ratio values were increased 
to a similar extent in groups II, III and IV compared with those 
in group I at weeks 4 and 8. There were no significant differ-
ences among groups II, III and IV at weeks 4 and 8.
MdA levels
serum MdA: The basal values of serum MDA in groups I, II, 
III and IV were 0.93±0.4 mmol/L, 0.84±0.3 mmol/L, 
0.86±0.2 mmol/L and 0.32±0.1 mmol/L, respectively, and were 
not significantly different among the groups except in group IV, 
which had a lower value than the other groups. The sequential 
changes in serum MDA in the four groups are shown in Figure 3. 
The values remained unchanged in group I but increased in 
group II at weeks 4 and 8 and in groups III and IV at week 4 
only with respect to zero time. The increases in groups III and 
IV were similar but lesser than those in group II at weeks 4 and 
8. Serum MDA values in group II were higher than those in 
groups I, III and IV at four and eight weeks. 
Aortic tissue MdA: The MDA contents of the aortic tissue in 
the four groups are shown in Table 1. The mean aortic MDA 
content from group I was 0.25±0.06 nmol/mg protein. The 
value in group II was 2.12-fold higher than that in group I. The 
values in groups III and IV were 73% and 75%, respectively, 
lower than in group II. The 1% cholesterol diet increased the 
levels of aortic tissue MDA while TQ at doses of 10 mg/kg/day 
and 20 mg/kg/day reduced these levels by 73% and 75%, 
respectively.  
Protein carbonyl levels
serum protein carbonyls: Serum protein carbonyl levels in the 
four groups at eight weeks are shown in Table 1. The mean 
serum protein carbonyl level in group I was 1.34±0.25 nmol/mL 
at the end of the eight weeks. The 1% cholesterol diet in group 
II increased the levels of serum protein carbonyls to a mean of 
5.34±1.36 nmol/mL. The values in groups III and IV were 
62% and 57%, respectively, lower than in group II. The 1% 
Table 1
Serum protein carbonyls and aortic malondialdehyde 
(MDa) and protein carbonyl levels in the four groups at 
eight weeks
 Group I Group II Group III Group IV
Serum protein  
carbonyl content, 
nmol/mL
1.34±0.25 5.34±1.36* 2.01±0.97** 2.27±0.4**
Aortic MDA,  
nmol/mg
0.25±0.06 0.53±0.32* 0.14±0.07** 0.13±0.06**
Aortic protein  
carbonyl content, 
nmol/mg
0.40±0.42 0.48±0.38 0.42±0.42 0.36±0.11
Results are expressed as mean ± SD. *P<0.05, group I versus other groups; 
**P<0.05, group II versus groups III and IV. Group I: normal diet; group II: 1% 
cholesterol diet; group III: 1% cholesterol diet plus thymoquinone 10 mg/kg/day; 
group IV: 1% cholesterol diet plus thymoquinone 20 mg/kg/day
Figure 3) Sequential changes in total cholesterol (TC)/high-density lipoprotein cholesterol (HDL-C) ratio and serum malondialdehyde  (MDA) 
in the four experimental groups. Results are expressed as mean ± SD. Group I: normal diet; group II: 1% cholesterol diet; group III: 1% 
cholesterol diet plus thymoquinone 10 mg/kg/day; group IV: 1% cholesterol diet plus thymoquinone 20 mg/kg/day. aP<0.05, zero time versus 
four and eight weeks in the respective groups; bP<0.05, group I versus other groups; cP<0.05, group II versus groups III or IV; eP<0.05, group 
IV versus other groups
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cholesterol diet increased the levels of serum protein carbonyls 
by 3.89-fold compared with the regular diet (group I), while 
TQ in groups III and IV produced inhibition of serum protein 
carbonyl levels by approximately 1.5-fold compared with the 
control group.
Aortic tissue protein carbonyls: Aortic tissue protein carbonyl 
levels of the four groups are summarized in Table 1. The mean 
protein carbonyl content of the aortic tissue from group I was 
0.40±0.42 nmol/mg protein. The values in all groups were 
similar.
histological effects
extent of atherosclerotic plaque formation: Representative 
photographs of the atherosclerotic changes in the intimal sur-
face of the aortas from each group are shown in Figure 4 and 
the results are summarized in Table 2. There were no athero-
sclerotic changes in the intimal surface of the aortas from 
group I. Significant areas of the intimal surfaces of aortas from 
groups II (45.08%±11.65%), III (27.81%±4.99%) and IV 
(20.67%±4.38%) were covered with atherosclerotic plaques. 
Administration of TQ at doses of 10 mg/kg/day and 20 mg/kg/
day reduced the development of atherosclerosis by 40% and 
53%, respectively. No significant difference was found between 
the effects of the two doses of TQ.
Microscopic changes in the aortic segments: Representative 
photographs of the histological sections of the aorta stained 
with H&E and the Accustain Elastic Stain Kit from the four 
groups are shown in Figures 5 and 6, respectively.
In Figure 5, the control group (group I) specimens showed 
normal arterial wall structure with no atherosclerotic chan-
ges. Group II showed moderate to severe atherosclerotic 
lesions. Administration of TQ at doses of 10 mg/kg/day and 
20 mg/kg/day with the 1% cholesterol diet, in groups III and 
IV, showed only mild localized areas of atherosclerosis.
In Figure 6, group I specimens were intact throughout the 
entire wall of the artery. Group II showed diffuse damage in the 
IEL at the sites of the atherosclerotic changes. Administration 
of TQ at doses of 10 mg/kg/day and 20 mg/kg/day with the 1% 
cholesterol diet, in groups III and IV, showed only focal damage 
in the IEL while most of the wall showed intact IEL.
Changes in intimal and medial thicknesses in the aortic seg-
ments: The intimal and medial surface areas and ratios are 
summarized in Table 2. The intimal and medial cross-sectional 
areas and the I/M ratio values in group I were 7.6±1.5 ×103 µm², 
52.3±9.7 ×103 µm² and 0.15±0.01 ×103 µm², respectively. Both 
the intimal cross-sectional area and I/M ratio values were 
increased by 4.3- and 3.5-fold, respectively, in group II while 
the medial cross-sectional area remained unchanged. 
Administration of TQ reduced the intimal cross-sectional area 
and I/M ratio by 52% and 45%, respectively, in group III, and by 
60% and 50%, respectively, in group IV. No significant differ-
ences were found between the effects of the two doses of TQ.
Table 2
atherosclerotic changes in the four groups
 Group I Group II Group III Group IV
Atherosclerosis 
(% of total 
intimal  
surface) 
0 45.08±11.65* 27.81±4.99*† 20.67±4.38*†
Intimal area 7.58±1.52 32.38±7.13* 15.54±6.86*† 13.31±4.23*†
Medial area 52.31±9.71 64.56±10.88 52.49±17.13 50.46±13.65
I/M ratio 0.15±0.01 0.52±0.06* 0.29±0.04*† 0.26±0.02*†
Results are expressed as mean ± SD. Intimal (I) and medial (M) surface areas 
are expressed as ×103 μm2. *P<0.05, group I versus other groups; †P<0.05, 
group II versus groups III and IV. Group I: normal diet; group II: 1% cholesterol 
diet; group III: 1% cholesterol diet plus thymoquinone 10 mg/kg/day; group IV: 
1% cholesterol diet plus thymoquinone 20 mg/kg/day
Figure 4) Representative photographs of the intimal surfaces of 
aortas from the four experimental groups showing Sudan IV-stained 
lipid deposits (dark staining in groups II, III and IV). Note the dif-
ference between the extent of atherosclerosis between group II and 
groups III and IV. Group I: normal diet; group II: 1% cholesterol 
diet; group III: 1% cholesterol diet plus thymoquinone 10 mg/kg/day; 
group IV: 1% cholesterol diet plus thymoquinone 20 mg/kg/day
Figure 5) Representative photographs of the microscopic changes from 
the four groups stained with hematoxylin and eosin. Note the normal 
arterial wall structure in group I (original magnification ×10), the 
increased intimal thickness in group II that involves most of the aortic 
circumference and the lesser thickness that involves much smaller por-
tions of the aortic circumference in groups III and IV (original magni-
fication ×4). Group I: normal diet; group II: 1% cholesterol diet; 
group III: 1% cholesterol diet plus thymoquinone 10 mg/kg/day; group 
IV: 1% cholesterol diet plus thymoquinone 20 mg/kg/day
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dIsCussIon
TQ doses used in the present study were similar to those used 
by other investigators. Based on that, there was no significant 
difference in the body weight gain among the studied groups, 
indicating that the various interventions did not affect the 
body weight. The high-cholesterol diet induced a significant 
increase in the serum levels of TC, TG, LDL-C, HDL-C and 
the TC/HDL-C ratio. Similar changes in the lipid profile were 
reported in several studies (4,16). Administration of TQ at a 
dose of 10 mg/kg/day reduced the levels of the TC, LDL-C and 
HDL-C. However, the TC/HDL-C ratio did not show any 
change due to the concomitant decreases in both TC and the 
HDL-C levels. The TG levels were not affected by TQ admin-
istration. No previous data are available on the effects of TQ 
on lipid profile in rabbits. However, Zaoui et al (11) reported 
that N sativa seed oil has a lipid-lowering effect in rats. TQ was 
also reported to produce significant reductions in the levels of 
TC, TG, LDL-C and HDL-C in albino rats, but with no linear 
dose- or time-dependent effect (17). The mechanism of these 
hypolipidemic effects is unknown. 
Consistent with previous reports (2,4,16), the present study 
demonstrated the coexistence of severe hyperlipidemia, enhanced 
ROS activity and atherosclerosis in this rabbit model. The study 
showed for the first time, to our knowledge, the increased levels 
of serum protein carbonyls in rabbits fed a high-cholesterol diet. 
Protein carbonyls are a marker of irreversible damage due to 
enhanced ROS activity (18), which validates this model for the 
study of ROS injury. The extent of atherosclerosis in the present 
study was 45% in the 1% cholesterol-fed group of rabbits. The 
cholesterol diet also increased the intimal cross-sectional area 
and I/M ratio 4.3 and 3.5 times,  respectively, compared with 
the control. The intimal cross-sectional area and I/M ratio 
were considered previously as markers for the severity of ath-
erosclerosis (15). Finally, the cholesterol diet induced marked 
destruction to the IEL. In the current study, the hypercholes-
terolemic atherosclerosis was associated with increases in the 
serum and aortic MDA and protein carbonyls, suggesting an 
increase in the levels of ROS. Several mechanisms were postu-
lated to explain the role of ROS in the pathogenesis of athero-
sclerosis. One of these mechanisms is the oxidation of LDL 
molecules to highly immunogenic oxidized LDL molecules in 
the presence of excess ROS (19). Oxidized LDL molecules are 
found in the subendothelial layers and help activate monocytes 
that are transformed into macrophages, upregulating their 
scavenger receptors and toll-like receptors that then phagocyt-
ose them. With progressive accumulation of oxidized LDL, 
macrophages modulate their phenotype, turning them into 
foam cells. Foam cells are the principal component of the fatty 
streaks, the first step in atheromatous plaque formation (20). 
ROS may also induce atherosclerosis by producing endothelial 
cell injury (21) and modulation of adhesion molecules (22).
The antiatherogenic effect of TQ may be due to its anti-
oxidant and/or anti-inflammatory effects. Previous in vitro and 
in vivo studies reported that TQ is a potent superoxide anion 
scavenger (10). TQ was also found to inhibit the cyclooxygen-
ase and lipoxygenase enzymes (23). Cyclooxygenase enzymes 
generate prostaglandins and thromboxane from arachidonic 
acid, while lipoxygenase enzymes catalyze the formation of 
leukotrienes (24). Oxygen radicals are produced during the 
synthesis of prostaglandins and leukotrienes (25). In the 
present study, the use of TQ decreased the levels of the serum 
and aortic MDA and the serum protein carbonyls, suggesting a 
decrease in the levels of the ROS. The higher dose of TQ did 
not further lower the levels of the serum or aortic MDA, or the 
serum protein carbonyls. Results from previous experiments 
also showed that increasing TQ dose over 10 mg/kg/day was 
not more beneficial in protecting rats against cisplatin-induced 
nephrotoxicity (26). The present study is the first to demon-
strate the effects of TQ on aortic MDA and protein carbonyls 
in hypercholesterolemic atherosclerotic rabbits. In other mod-
els, TQ administration significantly reduced the brain tissue 
MDA in ischemia-reperfusion injury (15), the hepatic MDA in 
carbon tetrachloride-induced hepatotoxicity (27) and the 
renal MDA in gentamicin-induced nephrotoxicity (28). The 
decrease in the levels of serum and aortic ROS induced by TQ 
is probably due to antioxidant properties of TQ (10). In the cur-
rent study, the antiatherosclerotic effect of TQ (10 mg/kg/day) 
was manifested in group III by a 40% decrease in the extent of 
atherosclerosis, a 52% decrease in the intimal surface area and 
a 45% decrease in the I/M ratio compared with group II. It also 
minimized hypercholesterolemia-induced damage in the IEL of 
the arteries. The 20 mg/kg/day dose showed 53%, 60% and 
50% decreases in the atheromatous and intimal areas and I/M 
ratio, respectively, in group IV. 
ConClusIon
TQ reduced the development of atherosclerosis and this was 
associated with reductions in serum lipids and oxidative stress. 
Increasing the dose of TQ from 10 mg/kg/day to 20 mg/kg/day 
was not associated with a further improvement. Further testing 
in humans is suggested.
limitations of the study
Caution should be exercised to interpret our results. 
Although our data indicate that reduction of oxidative 
Figure 6) Representative photographs of the microscopic changes from 
the four groups stained with elastic fibre stain. Note the black-stained 
elastic fibres, the relatively well-defined internal elastic lamina (IEL) 
and the poorly defined external elastic lamina (EEL) (original magni-
fication ×4). Group I: normal diet; group II: 1% cholesterol diet; 
group III: 1% cholesterol diet plus thymoquinone 10 mg/kg/day; 
group IV: 1% cholesterol diet plus thymoquinone 20 mg/kg/day
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stress and/or hyperlipidemia is associated with attenuation 
of atherosclerotic plaque development, it is plausible that TQ 
may have other functions independent of its effect on the ROS 
system.  Further work is necessary to identify the cause of 
reduction in lipid parameters by TQ. Of further interest, it 
would be important to study the macrophage content of ath-
erosclerotic lesions in rabbits with and without TQ treatment. 
Our data also do not address the potential toxicity of TQ. 
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